REPLICor 公布新数据

guilin2013

Montreal, Quebec – October 1, 2014
– Updated clinical trial data from REPLICor’s three Asian trials using its nucleic acid polymer (NAP) HBsAg-release inhibitors REP 2055 (REP 9AC) and REP 2139 (REP 9AC’) will be presented at the 10th Annual Meeting of the Oligonucleotide Therapeutics Society (OTS), to be held from Oct 12-16, 2014 in San Diego, CA.

REPLICor has currently tested its HBsAg-release inhibitor technology in three different clinical trials using different treatment modalities: in monotherapy, in combination with short term immunotherapy and in combination with a complete course of Pegasys™. Data presented by REPLCor during its presentation at the OTS meeting on Oct 15th will demonstrate 1) the unique ability of REPLICor’s NAP compounds to completely suppress HBsAg in the blood 2) the effect of HBsAg clearance on dramatically improving the activity of immunotherapy and 3) when used with a full course of Pegasys™, NAP therapy has resulted in the establishment of long term SVR in 80% of patients.

guilin2013

从REPLICor的三个亚洲试验用的核酸聚合物（NAP）的HBsAg释放抑制剂REP2055（REP9AC）和众议员2139（REP9AC'）更新临床试验数据将在寡核苷酸治疗学会第10届年度会议上提交（OTS），从10月12日至十六日，2014年在加利福尼亚州圣迭戈举行
REPLICor目前已经测试了它的HBsAg释放抑制剂技术在采用不同的治疗模式三种不同的临床试验：在单药治疗，在短期内免疫治疗，并与派罗欣™的一个完整的课程相结合的组合。它在OTS会议10月15日演讲时提出了REPLCor将展示一）REPLICor的NAP化合物完全抑制乙肝表面抗原在血液中2）HBsAg清除的效果上大大提高免疫活性的独特能力数据和3），当用派罗欣™的全过程中使用，NAP的治疗导致了80％的患者建立长期的SVR。

newchinabok

拿不出数据来

lgs1

svr
所谓病毒学响应
到底什么意思

我觉得如果抗原转阴才是起码要求吧
当然最好有抗体

如果仅仅病毒转阴，这个就意思不大
再加上价格对比，那跟恩替替诺比无意义了